Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments; Correction, 24191 [2023-08279]

Download as PDF Federal Register / Vol. 88, No. 75 / Wednesday, April 19, 2023 / Notices lotter on DSK11XQN23PROD with NOTICES1 438–7231; TTY (local): (301) 427–1130; Email: pso@ahrq.hhs.gov. SUPPLEMENTARY INFORMATION: DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Food and Drug Administration Background The Patient Safety Act, 42 U.S.C. 299b-21 to 299b-26, and the related Patient Safety Rule, 42 CFR part 3, published in the Federal Register on November 21, 2008 (73 FR 70732– 70814), establish a framework by which individuals and entities that meet the definition of provider in the Patient Safety Rule may voluntarily report information to PSOs listed by AHRQ, on a privileged and confidential basis, for the aggregation and analysis of patient safety work product. The Patient Safety Act authorizes the listing of PSOs, which are entities or component organizations whose mission and primary activity are to conduct activities to improve patient safety and the quality of health care delivery. HHS issued the Patient Safety Rule to implement the Patient Safety Act. AHRQ administers the provisions of the Patient Safety Act and Patient Safety Rule relating to the listing and operation of PSOs. The Patient Safety Rule authorizes AHRQ to list as a PSO an entity that attests that it meets the statutory and regulatory requirements for listing. A PSO can be ‘‘delisted’’ if it is found to no longer meet the requirements of the Patient Safety Act and Patient Safety Rule, when a PSO chooses to voluntarily relinquish its status as a PSO for any reason, or when a PSO’s listing expires. Section 3.108(d) of the Patient Safety Rule requires AHRQ to provide public notice when it removes an organization from the list of PSOs. AHRQ has accepted a notification of proposed voluntary relinquishment from the Emergency Medical Error Reduction Group PSO to voluntarily relinquish its status as a PSO. Accordingly, the Emergency Medical Error Reduction Group PSO, P0235, was delisted effective at 12:00 Midnight ET (2400) on March 29, 2023. More information on PSOs can be obtained through AHRQ’s PSO website at https://www.pso.ahrq.gov. Lisa Granger, Office of Policy, Planning, Legislation and International Affairs, Food and Drug Administration, 301– 796–9115, Lisa.Granger@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In the Federal Register of Tuesday, April 11, 2023 (88 FR 21688) in FR Doc. 2023– 248, the following corrections are made: 1. On page 21688, in the third column, in the header of the document, ‘‘Docket No. FDA–2023–N–0378’’ is corrected to read ‘‘Docket No. FDA– 2023–N–1338’’ and in the ADDRESSES section, in the third line of the last paragraph, ‘‘FDA–2023–N–0378’’ is corrected to read ‘‘FDA–2023–N–1338.’’ 2. On page 21689, in the first column, in the second line of the ‘‘Instructions:’’ section, Docket No. FDA–2023–N– 0378’’ is corrected to read ‘‘Docket No. FDA–2023–N–1338’’. Dated: April 13, 2023. Marquita Cullom, Associate Director. Dated: April 14, 2023. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2023–08247 Filed 4–18–23; 8:45 am] [FR Doc. 2023–08279 Filed 4–18–23; 8:45 am] BILLING CODE 4160–90–P BILLING CODE 4164–01–P VerDate Sep<11>2014 16:37 Apr 18, 2023 Jkt 259001 24191 [Docket No. FDA–2023–N–1338] [Docket No. FDA–2019–N–3065] Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments; Correction AGENCY: Food and Drug Administration, HHS. Notice; establishment of a public docket; request for comments; correction. ACTION: The Food and Drug Administration is correcting a notice entitled ‘‘Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments’’ that appeared in the Federal Register of April 11, 2023. The document announced a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee. The document was published with the incorrect docket number. This document corrects that error. SUMMARY: FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Products; Required Warnings for Cigarette Packages and Advertisements AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. SUMMARY: Submit written comments (including recommendations) on the collection of information by May 19, 2023. DATES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https:// www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under Review—Open for Public Comments’’ or by using the search function. The OMB control number for this information collection is 0910–0877. Also include the FDA docket number found in brackets in the heading of this document. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, PRAStaff@ fda.hhs.gov. In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. SUPPLEMENTARY INFORMATION: E:\FR\FM\19APN1.SGM 19APN1

Agencies

[Federal Register Volume 88, Number 75 (Wednesday, April 19, 2023)]
[Notices]
[Page 24191]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08279]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-1338]


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting; Establishment of a Public Docket; Request for 
Comments; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments; 
correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting; Establishment of a Public Docket; Request for 
Comments'' that appeared in the Federal Register of April 11, 2023. The 
document announced a forthcoming public advisory committee meeting of 
the Vaccines and Related Biological Products Advisory Committee. The 
document was published with the incorrect docket number. This document 
corrects that error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, 
Planning, Legislation and International Affairs, Food and Drug 
Administration, 301-796-9115, [email protected].

SUPPLEMENTARY INFORMATION: In the Federal Register of Tuesday, April 
11, 2023 (88 FR 21688) in FR Doc. 2023-248, the following corrections 
are made:
    1. On page 21688, in the third column, in the header of the 
document, ``Docket No. FDA-2023-N-0378'' is corrected to read ``Docket 
No. FDA-2023-N-1338'' and in the ADDRESSES section, in the third line 
of the last paragraph, ``FDA-2023-N-0378'' is corrected to read ``FDA-
2023-N-1338.''
    2. On page 21689, in the first column, in the second line of the 
``Instructions:'' section, Docket No. FDA-2023-N-0378'' is corrected to 
read ``Docket No. FDA-2023-N-1338''.

    Dated: April 14, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-08279 Filed 4-18-23; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.